Sarissa

Amarin Chairman & CEO Issue Letter to Shareholders

Retrieved on: 
Montag, Januar 22, 2024
Patient, Professional corporation, Sarissa, IPE, Share repurchase, Letter, Row, Management

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Chairman of the Board, Odysseas Kostas, M.D., and President & CEO, Patrick Holt, issued the following letter to Amarin shareholders:

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Chairman of the Board, Odysseas Kostas, M.D., and President & CEO, Patrick Holt, issued the following letter to Amarin shareholders:
    2023 was an important year for Amarin, marked by necessary transition and change.
  • With a new board focused on shareholders, we undertook significant actions to strengthen the Company.
  • The repurchase plan follows recent significant stock purchases by both Sarissa and our CEO, and further strengthens the alignment of incentives with our fellow shareholders.
  • Along with you, we believe Amarin has significant unrealized value not yet reflected in the current stock price.

Sarissa Capital Believes Amarin Stock Is Meaningfully Undervalued and Has Increased Its Ownership

Retrieved on: 
Montag, Dezember 4, 2023
Banking, Professional Services, Finance, Patient, Pershing Square Capital Management, Sarissa, Partnership, Professional corporation, Amarin

Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):

Key Points: 
  • Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):
    Sarissa believes Amarin’s stock is significantly undervalued.
  • We hope that recent progress detailed below will cause the stock to begin to reflect the value we think it has.
  • We have never sold any shares of Amarin and have only increased our position since we made the investment.
  • We are pleased with the progress that Amarin has made to date and expect the value to be reflected in the stock price over time.

Sarissa Capital Urges Alkermes Shareholders to Vote “FOR” Sarah Schlesinger and “WITHHOLD” Incumbent Director Richard Gaynor

Retrieved on: 
Mittwoch, Juni 28, 2023
Finance, Business, Banking, Professional Services, Other Professional Services, BLUE, Shareholder, Internet, Glenview Capital Management, Telephone, Annual, Annual Meetings of the International Monetary Fund and the World Bank Group, Wall Street, ALKS, Sequah Medicine Company, ARIAD Pharmaceuticals, ISS, Alkermes (company), Management, Security (finance), Alkermes, Sarissa

Shareholder pressure, including from Sarissa, has only incrementally moved the company in the right direction the last few years.

Key Points: 
  • Shareholder pressure, including from Sarissa, has only incrementally moved the company in the right direction the last few years.
  • If shareholders are not added to the board, we fear that Pops will continue to run the company as he pleases and never address its fundamental issues.
  • The board steadfastly refuses to add our nominees, including Sarah Schlesinger, who the Nom-Gov committee at Alkermes previously acknowledged would be a qualified board candidate and who ISS recommended that shareholders vote “FOR”.
  • Shareholders face an important decision at the upcoming Alkermes annual shareholder meeting.

Sarissa Issues Presentation Highlighting Sarissa Nominees Are Qualified to Create Value for Alkermes Shareholders

Retrieved on: 
Montag, Juni 26, 2023
Other Professional Services, Professional Services, Business, Finance, BLUE, Shareholder, Glenview Capital Management, Internet, Telephone, Annual, NUALS Arts and Literary Annual Meet, Wall Street, ALKS, Sarissa, Security (finance), Auction, Alkermes

We urge all shareholders to vote "FOR" the election of the Sarissa Nominees, “AGAINST” the compensation of the Company’s named executive officers, and "FOR" all other proposals in our proxy statement.

Key Points: 
  • We urge all shareholders to vote "FOR" the election of the Sarissa Nominees, “AGAINST” the compensation of the Company’s named executive officers, and "FOR" all other proposals in our proxy statement.
  • Shareholders are advised to read the definitive proxy statement and other documents related to the Annual Meeting as they contain important information.
  • The definitive proxy statement and other relevant documents are available at no charge on the SEC’s website at www.sec.gov .
  • The definitive proxy statement and other relevant documents filed by Sarissa Capital are also available at no charge at www.upgradealkermes.com or by directing a request to Sarissa Capital’s proxy solicitor, D.F.

Independent Proxy Advisory Firm ISS Agrees With Sarissa Capital That Shareholders’ Interests Would Be Best Served With Direct Shareholder Representation on the Alkermes Board

Retrieved on: 
Donnerstag, Juni 22, 2023
Banking, Professional Services, Finance, BLUE, Shareholder, Face, Internet, Glenview Capital Management, Telephone, Annual, Annual Meetings of the International Monetary Fund and the World Bank Group, Wall Street, Janssen, History, ALKS, Risk, Sarissa, ISS, Alkermes (company), Audit, Management, Security (finance), Alkermes

Shareholders should ask themselves a simple question – why would a purportedly well-functioning company undertake such actions?

Key Points: 
  • Shareholders should ask themselves a simple question – why would a purportedly well-functioning company undertake such actions?
  • Like ISS, we believe it is important to add direct shareholder representation to the Alkermes board.
  • The definitive proxy statement and other relevant documents are available at no charge on the SEC’s website at www.sec.gov .
  • The definitive proxy statement and other relevant documents filed by Sarissa Capital are also available at no charge at www.upgradealkermes.com or by directing a request to Sarissa Capital’s proxy solicitor, D.F.

Independent Proxy Advisory Firm ISS Concludes That Sarissa Capital Has Made a Compelling Case for Change to the Alkermes Board

Retrieved on: 
Dienstag, Juni 20, 2023
Banking, Professional Services, Finance, BLUE, Shareholder, Failure, Internet, Glenview Capital Management, Telephone, Annual, Annual Meetings of the International Monetary Fund and the World Bank Group, Wall Street, ALKS, Sarissa, ISS, Alkermes (company), Management, Security (finance), Auction, Alkermes

Sarissa Capital Management LP (“Sarissa”) today made the following announcement regarding the conclusion reached by independent proxy advisory firm ISS that Sarissa has made a compelling case for change to the board of directors of Alkermes plc (NASDAQ: ALKS):

Key Points: 
  • Sarissa Capital Management LP (“Sarissa”) today made the following announcement regarding the conclusion reached by independent proxy advisory firm ISS that Sarissa has made a compelling case for change to the board of directors of Alkermes plc (NASDAQ: ALKS):
    We are pleased that ISS recognizes the compelling case for change to the Alkermes board.
  • ISS also concludes that with the pending spin of its cancer business, the value of Alkermes’ incumbent director Richard Gaynor will be reduced and therefore he should be removed from the Alkermes board.
  • Fellow Alkermes shareholders face an important decision at our upcoming annual shareholder meeting.
  • Like ISS, we believe it is important to add direct shareholder representation to the Alkermes board.

Sarissa Issues Presentation Highlighting the Need for Shareholder Representation on the Alkermes Board

Retrieved on: 
Donnerstag, Juni 15, 2023
Professional Services, Finance, BLUE, Shareholder, Glenview Capital Management, Internet, Telephone, Annual, NUALS Arts and Literary Annual Meet, Wall Street, ALKS, Sarissa, Security (finance), Auction, Alkermes

Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the need for shareholder representation on the board of Alkermes plc (NASDAQ: ALKS) accessible at the link below:

Key Points: 
  • Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the need for shareholder representation on the board of Alkermes plc (NASDAQ: ALKS) accessible at the link below:
    If you have any questions regarding your BLUE universal proxy card or need assistance in executing your proxy card, please contact:
    Your vote at Alkermes' Annual General Meeting of Shareholders on June 29, 2023 is very important.
  • If you vote by internet or telephone, you will be required to provide the unique control number printed on your BLUE universal proxy card.
  • The definitive proxy statement and other relevant documents are available at no charge on the SEC’s website at www.sec.gov .
  • The definitive proxy statement and other relevant documents filed by Sarissa Capital are also available at no charge at www.upgradealkermes.com or by directing a request to Sarissa Capital’s proxy solicitor, D.F.

Sarissa Urges Shareholders to Vote for Sarissa Nominees to Provide Much Needed Oversight and Accountability to Alkermes

Retrieved on: 
Dienstag, Juni 13, 2023
Finance, Oncology, General Health, Health, Mental Health, Banking, Professional Services, Other Health, Pressure, BLUE, Shareholder, Internet, Biogen, Telephone, Annual, Clinical trial, Annual Meetings of the International Monetary Fund and the World Bank Group, Cancer, Wall Street, Sale, ALKS, NBI, Sarissa, Capital, Nature Biotechnology, Research, Fraud, Letter, Psychiatry, Alkermes (company), Management, Security (finance), Alkermes

Sarissa Capital today released the following letter to shareholders of Alkermes plc (NASDAQ: ALKS):

Key Points: 
  • Sarissa Capital today released the following letter to shareholders of Alkermes plc (NASDAQ: ALKS):
    We are one of Alkermes’ largest, long-term shareholders, owning nearly $450 million of stock.
  • We believe Pops understands that shareholder representation on the board will likely result in greater accountability and oversight.
  • Moreover, they each understand that they work for the shareholders and will provide essential oversight of management and accountability to shareholders.
  • We urge our fellow Alkermes shareholders to vote the BLUE universal proxy card “FOR” all Sarissa Nominees to provide much needed oversight and accountability at Alkermes.

Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors

Retrieved on: 
Dienstag, Juni 13, 2023
Lead, Drug development, Central nervous system, Judgement, Senior, Redundancy, Marketing, Ironwood Pharmaceuticals, Brigham and Women's Hospital, Corporate governance, Associate, Harvard Medical School, Neuroscience, Interview, Alkermes, Patient, Translational research, Cato T. Laurencin, Neurology, Hospital, R, Therapy, Vertex Pharmaceuticals, Medical device, Management, Computer data storage, Security (finance), Vertex, Sarissa

DUBLIN, June 13, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual General Meeting of Shareholders (the Annual Meeting), which is scheduled to be held on June 29, 2023.

Key Points: 
  • 8 of 11 directors have life sciences industry experience; 7 of 11 directors have scientific expertise and/or R&D experience; and 4 of 11 directors possess Doctor of Medicine degrees.
  • Skills are Redundant to the Current Refreshed Board3; Limited Experience
    Ms. Bonfiglio has limited operational experience and minimal public company Board experience.
  • 11 of 11 directors have corporate strategy and/or business development experience; 7 of 11 directors have more finance/accounting experience; 11 of 11 directors have more public company board and/or management experience.
  • The current directors possess significant experience and deep expertise in areas critical to the Company's continued execution of its business strategy, including neuroscience experience; finance and/or transactional experience; commercial marketing and sales experience; medical/R&D experience; and global business experience.

Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors

Retrieved on: 
Dienstag, Juni 13, 2023
Lead, Drug development, Central nervous system, Judgement, Senior, Redundancy, Marketing, Ironwood Pharmaceuticals, Brigham and Women's Hospital, Corporate governance, Associate, Harvard Medical School, Neuroscience, Interview, Alkermes, Patient, Translational research, Cato T. Laurencin, Neurology, Hospital, R, Therapy, Vertex Pharmaceuticals, Medical device, Management, Computer data storage, Security (finance), Vertex, Sarissa

DUBLIN, June 13, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual General Meeting of Shareholders (the Annual Meeting), which is scheduled to be held on June 29, 2023.

Key Points: 
  • 8 of 11 directors have life sciences industry experience; 7 of 11 directors have scientific expertise and/or R&D experience; and 4 of 11 directors possess Doctor of Medicine degrees.
  • Skills are Redundant to the Current Refreshed Board3; Limited Experience
    Ms. Bonfiglio has limited operational experience and minimal public company Board experience.
  • 11 of 11 directors have corporate strategy and/or business development experience; 7 of 11 directors have more finance/accounting experience; 11 of 11 directors have more public company board and/or management experience.
  • The current directors possess significant experience and deep expertise in areas critical to the Company's continued execution of its business strategy, including neuroscience experience; finance and/or transactional experience; commercial marketing and sales experience; medical/R&D experience; and global business experience.